Matthew Johnson

Overview

Matthew Johnson is presented in the source as a Johns Hopkins psychiatry professor and psychedelic researcher studying clinical effects, risks, therapeutic protocols, and drug policy.

Current Profile

In Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson, Johnson distinguishes classic serotonin 2A psychedelics from ketamine, MDMA, salvinorin A, and other altered-state compounds. He treats psychedelic therapy as a structured clinical intervention involving screening, preparation, monitored dosing, and Psychedelic Integration, not as a synonym for taking a drug.

His account is cautiously mechanistic. Changes in self-representation, agency, and the emotional meaning of memories may help explain durable behavioral change, but these remain educated hypotheses. He is skeptical of strong microdosing claims, separates persistent perceptual disorder from flashback folklore, emphasizes psychiatric and environmental risks, and describes adolescent, traumatic-brain-injury, and regulatory questions as unresolved.

Key Characteristics

• Differentiates compounds by pharmacology, subjective effects, evidence, and clinical use rather than treating all altered-state drugs as one class.
• Frames preparation, monitoring, therapeutic support, and follow-up as constitutive parts of psychedelic therapy.
• Proposes self-representation, agency, and memory reappraisal as candidate change mechanisms.
• Calibrates claims by separating controlled findings, educated speculation, anecdote, and policy forecast.
• Rejects strong microdosing benefit claims on the controlled evidence discussed and raises a theoretical repeated-exposure safety concern.
• Supports regulated, diagnosis-specific clinical pathways rather than casual or retail-style access.

Evidence

• Compound and mechanism distinctions - Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson separates classic psychedelics, ketamine, MDMA, and salvinorin A while describing candidate receptor and experience-level mechanisms.
• Clinical protocol - Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson describes psychiatric and cardiovascular screening, preparation, supervised dosing, physiological monitoring, writing, and next-day integration.
• Evidence calibration - Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson distinguishes established findings from hypotheses about microdosing, memory reconsolidation, adolescents, traumatic brain injury, and regulation.
• Safety boundary - Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson discusses psychiatric contraindications, unsafe-setting harms, persistent perceptual symptoms, and the limits of controlled-study generalization.

Qualifications

This profile is bounded to one September 2021 interview summary, not Johnson’s full publication record, current institutional role, or later evidence. The episode’s doses, receptor claims, study status, legal descriptions, and forecasts are historical and source-scoped. The page does not establish efficacy, eligibility, legal access, or safe self-administration.

What Changed

• Created a source-bounded profile connecting Johnson’s clinical-protocol, mechanism, evidence-calibration, safety, and regulation views.

Relationships

• Andrew Huberman - interviewer who elicits the clinical, mechanistic, and safety framework.
• Psychedelic Therapy Mechanism - combined biological, experiential, and therapeutic model Johnson discusses.
• Psychedelic Integration - writing and follow-up process used after the acute session.
• Psychedelic Clinical Supervision Boundary - screening and safety rule reinforced throughout the interview.
• Psychedelic Microdosing Evidence - evidence area Johnson treats skeptically.
• Memory Reconsolidation Psychiatry - adjacent hypothesis for changed relations to traumatic memories.